Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gynecologic 1Dermatologic 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Sarcoma, Synovial 1Melanoma 1Advanced Fallopian Tube Carcinoma 1

Interventions

Cyclophosphamide 6fludarabine 4Doxorubicin 4Ifosfamide 3Injections 2Imatinib Mesylate 2Filgrastim 2perifosine 1fludarabine phosphate 1brostallicin 1aldesleukin 1Trabectedin 1Temozolomide 1Sunitinib 1Radiotherapy 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Mass Spectrometry 1Leukapheresis 1Interleukin-2 1Immunotherapy, Adoptive 1Immunotherapy 1Drug Therapy 1Decitabine 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biological Therapy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × Leukapheresis × Gynecologic × Clear all
NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡